Document Detail


Is cardiac resynchronization therapy an antiarrhythmic therapy for atrial fibrillation? A systematic review and meta-analysis.
MedLine Citation:
PMID:  23299710     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The impact of cardiac resynchronization therapy (CRT) on atrial fibrillation (AF) burden is poorly characterized. To assess the influence of CRT on AF, we performed a systematic literature search in MEDLINE using the MeSH headings "cardiac resynchronization therapy" or "cardiac pacing, artificial" and "atrial fibrillation." Selected studies were peer-reviewed and written in English. Most studies enrolled patients meeting traditional CRT criteria. Ten observational studies and two secondary analyses of clinical trials were identified. Although ten studies suggest that CRT favorably impacts AF, one secondary analysis of a clinical trial showed no effect of CRT on new-onset AF. In a meta-analysis of three studies examining the effect of CRT on persistent or permanent AF, the combined rate of conversion from persistent or permanent AF to sinus rhythm was 0.107 (95 % confidence interval 0.069-0.163). Prospective studies, particularly among patients not meeting traditional CRT criteria, are needed.
Authors:
Paul L Hess; Kevin P Jackson; Vic Hasselblad; Sana M Al-Khatib
Publication Detail:
Type:  Journal Article; Meta-Analysis; Review    
Journal Detail:
Title:  Current cardiology reports     Volume:  15     ISSN:  1534-3170     ISO Abbreviation:  Curr Cardiol Rep     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-09     Completed Date:  2013-06-25     Revised Date:  2014-02-04    
Medline Journal Info:
Nlm Unique ID:  100888969     Medline TA:  Curr Cardiol Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  330     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Atrial Fibrillation / therapy*
Cardiac Resynchronization Therapy*
Humans
Treatment Outcome
Grant Support
ID/Acronym/Agency:
T32 HL069749/HL/NHLBI NIH HHS
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  One-pot synthesis of branched palladium nanodendrites with superior electrocatalytic performance.
Next Document:  Update on type 2 diabetes as a cardiovascular disease risk equivalent.